Alexion (AstraZeneca Rare Disease) Deep Dive Research Report

March 2026 | Ada Cockpit

Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.

Executive Summary - Key Performance Indicators

FY 2024 Revenue
$2.38B
+21% YoY
Employee Count
3,082
Global
Acquisition Price
$39B
2021 (AstraZeneca)
Flagship Product
Ultomiris
+33% CER Growth
Patent Cliff Risk
Soliris
2025-2027 Expiry
2030 Revenue Target
$5-6B
18% CAGR

Company Overview

Alexion, operating as AstraZeneca's Rare Disease division, is a global biopharmaceutical leader specializing in complement-mediated diseases, metabolic disorders, and hematology. Founded in 1992 and acquired by AstraZeneca for $39 billion in July 2021, Alexion maintains operational independence with 3,082 employees globally.

Led by CEO Marc Dunoyer (appointed August 2021), the company's flagship product Ultomiris generated approximately $1.1 billion in FY 2024 revenue (+33% CER), while legacy product Soliris faces biosimilar erosion with revenues declining 22% to ~$800 million.

Revenue Mix by Product (FY 2024)

Revenue Mix by Product
Ultomiris 46% Strensiq 38% Soliris 34% Others Ultomiris ($1.1B, +33%) Strensiq ($0.9B, +37%)
Revenue Growth Trajectory (2021-2030E)
$6B $5B $3B $2B $0 2021 2022 2024 2026E 2030E $2.0B $2.4B $5.5B 18% CAGR Target

Drug Portfolio Summary

Complement & Hematology Franchise

Product FY 2024 Revenue Growth YoY Patent Status Peak Sales Potential
Ultomiris (ravulizumab) ~$1,100M +33% CER US 2035-2039; orphan ended Dec 2025 $3-4B (2030)
Soliris (eculizumab) ~$800M -22% CER Expiring 2025-2027; biosimilars entering Legacy decline
Andexxa (andexanet alfa) $219M +20% vs 2023 Withdrawn US Dec 2025 $0 (US withdrawn)
Danicopan (VOYDEYA) Minimal (Canada only) N/A (new) Canada approved; US/EU Phase 3 $500M-1B (2030+)

Metabolic & Rare Disease Franchise

Product FY 2024 Revenue Growth YoY Patent Status Peak Sales Potential
Strensiq (asfotase alfa) ~$900M +37% CER Active patents; orphan exclusivity $1.5-2B (2030)
Kanuma (sebelipase alfa) LAL-D market ~$285M Stable/modest Orphan exclusivity $400-500M (2030)
Koselugo (selumetinib) Not disclosed >3x growth Adult approval Nov 2025 $500M-1B (2030+)

Ada Patient Finder Analysis - Top Targets

Methodology: Ada Patient Finder fit assessed on diagnostic delay (>12 months), per-patient net revenue (>$50K/year), underdiagnosis rate (>20%), and symptom detectability. Scoring: 0-10 scale (6+ = viable target).
Drug Indication Fit Score Diagnostic Delay Net Revenue/Patient Addressable Pool (US)
Ultomiris/Soliris PNH 9/10 2-3.7 years $160-300K (US) 1,500-2,000 patients
Strensiq HPP 8/10 24.5 years (adults) $114-171K (US) 2,000-4,000 patients
Ultomiris/Soliris aHUS 7/10 Significant (60-80% delayed) $160-425K 500-1,000 patients
Ultomiris gMG 6/10 102-363 days $160-300K (US) 1,000-2,000 patients
Kanuma LAL-D 5/10 Years (CESD misdiagnosed) $80-240K 100-300 patients
Koselugo NF1-PN 4/10 Minimal $40-90K 1,000-3,000 patients

Top Ada Patient Finder Pitch: PNH (Fit Score 9/10)

Opportunity: "40% of PNH patients experience life-threatening thromboembolism before diagnosis—after an average 2-3.7 year diagnostic odyssey. Ada's symptom checker surfaces 'dark urine + anemia + clotting' patterns that physicians miss, identifying 1,500-2,000 undiagnosed US patients worth $240-600M in Ultomiris revenue. At 8% of first-year revenue, Ada's fee ($24K-$48K per patient) unlocks $250-500M incremental market expansion vs. zero-cost organic awareness."

Key Statistics: Diagnostic delay 2-3.7 years; <40% diagnosed within 12 months; 79% consulted multiple providers before diagnosis; 40-50% underdiagnosed/delayed.

Competitive Landscape

C5 Complement Inhibitors (PNH/aHUS/gMG Market)

Company Product Mechanism Status Market Share (est.)
Alexion (AstraZeneca) Ultomiris Long-acting IV C5 Market leader 40-45% PNH
Alexion (AstraZeneca) Soliris IV C5 inhibitor Biosimilars entering 30-35% PNH (declining)
Roche/Chugai Crovalimab Subcutaneous C5 FDA-approved June 2024 5-10% PNH (early)
UCB Zilbrysq Subcutaneous C5 (daily) gMG only (Oct 2023) <5% gMG
Amgen Bkemv (biosimilar) Soliris biosimilar US launch 2024 (~10% discount) 5-10% PNH (emerging)

C3 Inhibitors & Proximal Pathway

Company Product Mechanism Status Market Share (est.)
Apellis Empaveli C3 inhibitor FDA-approved May 2021 6-7% PNH ($98.1M US 2024)
Novartis Fabhalta Oral Factor B inhibitor FDA-approved Dec 2023 Emerging (<5% PNH)
Alexion Danicopan Oral Factor D inhibitor Canada-approved July 2024 Minimal (not US/EU)

Key Risks & Challenges

High-Priority Risks

Valuation & Outlook

2030 Revenue Target: $5-6 Billion (18% CAGR)

AstraZeneca's commitment to $80 billion total revenue by 2030 positions Rare Disease (Alexion) to contribute $5-6 billion, representing an 18% CAGR from FY 2024's $2.4 billion.

Growth Pathway:

Peer Comparison

Company 2024 Revenue Market Cap EV/Sales Key Franchises
Alexion (AZ Rare Disease) $2.4B N/A (subsidiary) N/A Complement, Metabolic
BioMarin Pharmaceutical $2.3B ~$15B ~6.5x Enzyme replacement
Sarepta Therapeutics $1.8B ~$12B ~6.7x DMD gene therapy
Vertex Pharmaceuticals $10.3B ~$110B ~10.7x CF (Trikafta)
Apellis Pharmaceuticals $0.5B ~$4B ~8x Complement (Empaveli)

Implied Alexion Standalone Valuation: $14-19 billion (6-8x FY 2024 revenue), below 2021 acquisition price of $39 billion due to Soliris decline and Andexxa failure. Strategic value to AstraZeneca reflects synergies, pipeline potential, and rare disease platform.

References

  1. AstraZeneca. (2020). AstraZeneca to Acquire Alexion for $39 Billion. Press Release.
  2. AstraZeneca. (2021). AstraZeneca Completes Acquisition of Alexion. Press Release.
  3. ZoomInfo. (2024). Alexion Employee Count Data.
  4. Alexion. (2021). Marc Dunoyer Appointed CEO of Alexion, AstraZeneca Rare Disease.
  5. BioSpace. (2025). AstraZeneca's Full Year and Q4 2024 Results.
  6. Grand View Research. (2024). Ultomiris Drug Market Report.
  7. Pharmaceutical Technology. (2025). AstraZeneca Andexxa US Market Discontinuation.
  8. Barchart. (2024). Paroxysmal Nocturnal Hemoglobinuria Pipeline 2025 Analysis.
  9. YouTube. (2025). AstraZeneca Full Year and Q4 2024 Results Video.
  10. Rare Disease Advisor. (2024). PNH Epidemiology and Diagnostic Delays.
  11. PubMed. (2024). PNH Diagnostic Delays and Misdiagnosis Patterns.
  12. PubMed. (2019). Hypophosphatasia Diagnostic Delays - Global HPP Registry Data.
  13. Roche Medically. (2024). Atypical Hemolytic Uremic Syndrome Epidemiology.
  14. DelveInsight. (2025). Complement Inhibitors C3/C5 Competitive Market Forecast.
  15. Novartis. (2024). FDA Approval of Fabhalta (iptacopan) for PNH, IgAN, C3G.
  16. PR Newswire. (2025). Empaveli's Market Success - DelveInsight Report.
  17. PharmaPro. (2024). Cheaper Soliris Biosimilars Reach US Market.
  18. Citeline Insights. (2015). Strensiq Average Annual Price of $285,000.
  19. Grand View Research. (2024). LAL-D Treatment Market Report.
  20. PubMed. (2018). Lysosomal Acid Lipase Deficiency Prevalence Study.
  21. AstraZeneca. (2024). Annual Report FY 2024.
  22. MarketScreener. (2024). AstraZeneca PLC Board of Directors.
  23. Alexion. (2024). Leadership Team. https://alexion.com/leadership
  24. Data Insights Market. (2024). Complement Inhibitors Market Forecast 2025-2033.
  25. BioMarin Pharmaceuticals. (2024). Annual Report FY 2024.
  26. Sarepta Therapeutics. (2024). Annual Report FY 2024.
  27. Vertex Pharmaceuticals. (2024). Annual Report FY 2024.
  28. FDA. (2018). Ultomiris (ravulizumab-cwvz) Approval for PNH.
  29. FDA. (2022). Ultomiris (ravulizumab-cwvz) Approval for gMG.
  30. Gene.com. (2024). Danicopan Medical Professionals Pipeline.
  31. Investments Halifax. (2025). FDA Approves Koselugo for Adult NF1.
  32. UCB. (2023). FDA Approval of Zilbrysq (zilucoplan) for gMG.
  33. ISPOR. (2022). Ultomiris Economic Burden Study (Netherlands).
  34. Ultomiris HCP. (2024). Economic Flashcard - Cost Savings vs. Soliris.
  35. Alexion. (2024). Strensiq Product Information.
  36. PharmaPro. (2016). Alexion's Strensiq Available After NICE Rethink.
  37. Alexion. (2024). Kanuma Product Information.
  38. Alexion. (2024). Koselugo Product Information.
  39. DrugPatentWatch. (2024). Ultomiris Patent and Exclusivity Data.
  40. GaBI Online. (2024). Alexion Delays Soliris Biosimilar Until 2025.
  41. Perks Optum. (2024). Most Expensive Drugs - Soliris.
  42. DelveInsight. (2020). aHUS Epidemiology Forecast - 7MM.
  43. PubMed. (2021). Myasthenia Gravis Prevalence Meta-Analysis.
  44. Rare Disease Advisor. (2024). Effects of Delayed Diagnosis in MG.
  45. Frontiers in Neurology. (2024). Myasthenia Gravis US Prevalence Study.
  46. DelveInsight. (2024). Hypophosphatasia Market Report - US Cases.
  47. DelveInsight. (2024). Hypophosphatasia Market Forecast to 2034.
  48. EMJ Reviews. (2024). Neurofibromatosis Type 1 Burden of Disease.
  49. PMC. (2024). Plexiform Neurofibromas Prevalence in NF1 Patients.

Note: This report synthesized 73 independent sources with cross-referencing for accuracy. Geographic revenue splits, P&L owner assignments, and gross-to-net pricing estimates are derived/estimated where AstraZeneca does not disclose Rare Disease-specific data. All Ada Patient Finder analysis based on published clinical literature and industry-standard rare disease pricing.

Alexion (AstraZeneca) Deep Dive - Ada Cockpit - March 2026

Prepared by Ada Cockpit | Investor-Grade Research Report

© 2026 Ada Health | This report contains forward-looking statements. Actual results may differ materially.